349 related articles for article (PubMed ID: 20445015)
41. Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease.
Müller T; Riederer P; Grünblatt E
J Neural Transm (Vienna); 2017 Jun; 124(6):745-748. PubMed ID: 28299453
[TBL] [Abstract][Full Text] [Related]
42. Cardiac safety of rasagiline, a selective monoamine oxidase type B inhibitor for the treatment of Parkinson's disease: a thorough QT/QTc study.
Mendzelevski B; Sprenger CR; Spiegelstein O; Rabinovich-Guilatt L
Int J Clin Pharmacol Ther; 2014 Mar; 52(3):192-201. PubMed ID: 24447649
[TBL] [Abstract][Full Text] [Related]
43. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.
Amsterdam JD
J Clin Psychiatry; 2003 Feb; 64(2):208-14. PubMed ID: 12633131
[TBL] [Abstract][Full Text] [Related]
44. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
[TBL] [Abstract][Full Text] [Related]
45. Hydride Abstraction as the Rate-Limiting Step of the Irreversible Inhibition of Monoamine Oxidase B by Rasagiline and Selegiline: A Computational Empirical Valence Bond Study.
Tandarić T; Prah A; Stare J; Mavri J; Vianello R
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32858935
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study.
Cereda E; Cilia R; Canesi M; Tesei S; Mariani CB; Zecchinelli AL; Pezzoli G
J Neurol; 2017 Jun; 264(6):1254-1263. PubMed ID: 28550482
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetics, Pharmacodynamics, and Safety of a Single Escalating Dose and Repeated Doses of Rasagiline Transdermal Patch in Healthy Chinese Subjects.
Wang M; Zhou W; Zhang Q; Zong S; Lv C
Clin Pharmacol Drug Dev; 2020 Jul; 9(5):602-609. PubMed ID: 31823527
[TBL] [Abstract][Full Text] [Related]
48. Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline.
Degli Esposti L; Piccinni C; Sangiorgi D; Nobili F; Buda S
Neurol Sci; 2016 Feb; 37(2):227-34. PubMed ID: 26474874
[TBL] [Abstract][Full Text] [Related]
49. Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro.
Dimpfel W; Hoffmann JA
BMC Pharmacol; 2011 Feb; 11():2. PubMed ID: 21338509
[TBL] [Abstract][Full Text] [Related]
50. Electropharmacograms of rasagiline, its metabolite aminoindan and selegiline in the freely moving rat.
Dimpfel W; Hoffmann JA
Neuropsychobiology; 2010; 62(4):213-20. PubMed ID: 20714170
[TBL] [Abstract][Full Text] [Related]
51. A double-blind, delayed-start trial of rasagiline in Parkinson's disease.
Olanow CW; Rascol O; Hauser R; Feigin PD; Jankovic J; Lang A; Langston W; Melamed E; Poewe W; Stocchi F; Tolosa E;
N Engl J Med; 2009 Sep; 361(13):1268-78. PubMed ID: 19776408
[TBL] [Abstract][Full Text] [Related]
52. [The use of a new MAO B inhibitor rasagiline in the treatment of motor fluctuations in Parkinson's disease].
Levin OS
Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(9):91-6. PubMed ID: 19004128
[No Abstract] [Full Text] [Related]
53. Rasagiline: a review of its use in the management of Parkinson's disease.
Oldfield V; Keating GM; Perry CM
Drugs; 2007; 67(12):1725-47. PubMed ID: 17683172
[TBL] [Abstract][Full Text] [Related]
54. Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat.
Finberg JP; Gross A; Bar-Am O; Friedman R; Loboda Y; Youdim MB
Br J Pharmacol; 2006 Nov; 149(6):647-56. PubMed ID: 17016505
[TBL] [Abstract][Full Text] [Related]
55. A critical appraisal of MAO-B inhibitors in the treatment of Parkinson's disease.
Jost WH
J Neural Transm (Vienna); 2022 Jun; 129(5-6):723-736. PubMed ID: 35107654
[TBL] [Abstract][Full Text] [Related]
56. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
Youdim MB; Weinstock M
Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
[TBL] [Abstract][Full Text] [Related]
57. Rasagiline, an inhibitor of MAO-B, decreases colonic motility through elevating colonic dopamine content.
Liu CZ; Zhang XL; Zhou L; Wang T; Quan ZS; Zhang Y; Li J; Li GW; Zheng LF; Li LS; Zhu JX
Neurogastroenterol Motil; 2018 Nov; 30(11):e13390. PubMed ID: 29956417
[TBL] [Abstract][Full Text] [Related]
58. Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson's disease.
Solís-García del Pozo J; Mínguez-Mínguez S; de Groot PW; Jordán J
Expert Opin Drug Saf; 2013 Jul; 12(4):479-86. PubMed ID: 23634791
[TBL] [Abstract][Full Text] [Related]
59. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
Weinreb O; Amit T; Bar-Am O; Youdim MB
Prog Neurobiol; 2010 Nov; 92(3):330-44. PubMed ID: 20600573
[TBL] [Abstract][Full Text] [Related]
60. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.
Tolosa E; Stern MB
Eur J Neurol; 2012 Feb; 19(2):258-64. PubMed ID: 21819487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
